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The aim of this study was to assess the relationship between haemoglobin level and quality-of-life in anaemic cancer patients.
Patients, diagnosed with one of four cancers, were recruited if their haemoglobin level was 512 g dl
71 (female) or
513 g dl
71 (male). The condition-speciﬁc Functional Assessment of Cancer Therapy – Anaemia and the generic SF-36 were
used to assess quality-of-life. Thirty-six per cent of the 179 recruited patients had breast cancer, 28% ovarian cancer, 25% lung
cancer, and 11% multiple myeloma. Their mean (s.d.) haemoglobin level was 10.66 (1.04) g dl
71. Partial correlations
controlling for the potentially confounding effects of age, gender, and time since diagnosis found signiﬁcant positive
relationships between haemoglobin and all domains of the Functional Assessment of Cancer Therapy – Anaemia, and with all
but two of the SF-36 domains. On linear regression controlling for the same factors, each unit haemoglobin rise equalled an
average 8.19 Functional Assessment of Cancer Therapy – Anaemia, and an average 6.88 Functional Assessment of Cancer
Therapy–Fatigue, increase. Haemoglobin accounted for a similar amount of variability (8%) in SF-36 scores. In conclusion,
quality-of-life has been found to be signiﬁcantly positively related to haemoglobin level in anaemic cancer patients. This
suggests that normalisation of haemoglobin in cancer patients is likely to increase their quality-of-life. The greater sensitivity of
the condition-speciﬁc Functional Assessment of Cancer Therapy – Anaemia compared with the generic SF-36 suggests that
the Functional Assessment of Cancer Therapy – Anaemia can be used alone to assess quality-of life in this patient group.
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Anaemia is deﬁned as ‘a deﬁciency of either red blood cells (RBCs)
or lack of haemoglobin, which leads to a reduction in the oxygen-
carrying capacity of blood’ (Yellen et al, 1997). This deﬁciency may
result from shortened red blood cell survival, deranged iron meta-
bolism, or relative erythropoietin deﬁciency (Vijayakamar et al,
1993). Anaemia is a common condition in patients with malig-
nancy. Up to 30% of patients with solid tumours are reported to
have anaemia, with anaemia being particularly common among
those with more advanced disease (Malik et al, 1998). While anae-
mia is associated with most chronic conditions, the anaemia of
malignancy may be a consequence of both myelosupression of stem
cells by tumour cell products, such as tumour necrosis factor, and
cytotoxic therapy. Anaemia is associated with symptoms of fatigue,
lethargy, dyspnoea, loss of appetite and inability to concentrate.
Fatigue, a multifactorial symptom, is the most frequently reported
symptom in cancer patients (Winningham et al, 1994). However,
despite the high prevalence of cancer-related fatigue, and its
improvement with increase in haemoglobin level (e.g. Glaspy et
al, 1997), its speciﬁc aetiology is not well understood (Cella,
1997b). Related to the reported fatigue are effects on the patient’s
subjective sense of well-being in that the chores of everyday life
become a burden, exercise tolerance is decreased and social activity
is curtailed due to lack of energy (Leitgeb et al, 1994). Thus the
symptoms of anaemia involve both physical and emotional
problems with consequent deterioration in health related quality-
of-life.
Health-related quality of life (HRQoL) is a broad, subjective,
and multidimensional concept that encompasses physical health
and symptoms, functional status and activities of daily life, mental
well-being and social health, including social role functioning. This
distinguishes between quality of life (QoL) in its more general
sense (an ill-deﬁned term, with most deﬁnitions emphasising
components of happiness and satisfaction with life) and QoL as
appropriate for the requirements of clinical medicine and clinical
trials (Fayers and Machin, 2000). The broadness of the deﬁnition
of HRQoL means that multidimensional scales are needed in its
measurement (Spilker, 1990; Bowling, 1991).
The use of reliable and well-validated HRQoL measures in
patients with anaemia allows assessment of the impact of the
condition and, importantly, assessment of the efﬁcacy of treatment.
However, many of the published QoL studies in anaemic cancer
patients have tended to employ generic and non-speciﬁc scales
such as the WHO Performance Status Indicator (Ludwig et al,
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ment (LASA, also known as CLAS, Cancer Linear Analogue Scale)
(Abels, 1992, 1993; Case et al, 1993; Vijayakumar et al, 1993; Glas-
py et al, 1997).
The Functional Assessment of Cancer Therapy-Anaemia (FACT-
An) is an anaemia speciﬁc scale which was developed in the late
1990s speciﬁcally for use in anaemic cancer patients (Cella,
1997a,b). It is a condition-speciﬁc quality-of-life instrument, devel-
oped to assess the impact of fatigue (FACT-F) and other anaemia-
related symptoms on quality-of-life in patients with cancer, which
forms part of the FACIT (Functional Assessment of Chronic Illness
Therapy) quality-of-life measure. The psychometric properties of
the anaemia (FACT-An) and fatigue (FACT-F) subscales with
cancer patients have been assessed (Yellen et al, 1997), and the
FACT-An has been validated as an outcome measure for cancer
related anaemia (Cella and Bonomi, 1996; Cella, 1997, 1998; Cella
and Webster, 1997; Yellen et al, 1997).
The relationship between haemoglobin level and quality-of-life
in anaemic cancer patients has been assessed using both the FACT
and other measurement scales. Studies using the FACT have found
that both the anaemia speciﬁc (FACT-An) and fatigue-speciﬁc
(FACT-F) scales signiﬁcantly differentiate patients by haemoglobin
level (Yellen et al, 1997; Cella, 1998). Cella and Webster (1997)
used the FACT-An to compare the quality-of-life of patients whose
haemoglobin levels were 412 g dl
71 with those having haemoglo-
bin levels 412 g dl
71. The FACT-An was able to discriminate
between patients according to haemoglobin levels; those with
haemoglobin levels 412 g dl
71 reporting signiﬁcantly less fatigue
(P=0.01), fewer non-fatigue anaemia symptoms (P=0.016), better
physical well-being (P=0.003), better functional well-being
(P=0.001), and higher total (FACT-G) quality-of-life (P=0.003)
than those with lower haemoglobin levels. Studies using measure-
ment scales other than the FACT have generally found positive
associations (moderate but statistically signiﬁcant) between haemo-
globin level and quality-of-life score (Abels, 1993; Case et al, 1993;
Leitgeb et al, 1994; Ludwig et al, 1995; Glaspy et al, 1997; Malik et
al, 1998; Sweeney et al, 1998).
While associations have been found between haemoglobin levels
and quality-of-life in cross-sectional analyses, follow-up analyses of
treated patients have also generally shown that the greater the
increase in haemoglobin levels following Epoetin alfa (recombinant
human erythropoietin) treatment the greater the improvement in
quality-of-life as assessed by the FACT (Glaspy et al, 1997; Demetri
et al, 1998; Littlewood et al, 1998; Cleeland et al, 1999). Indeed, a
review of the literature by Beguin (1998) concluded that Epoetin alfa
therapy is associated with substantial improvements in quality-of-life
and, moreover, that the improvements are proportional to changes
in haemoglobin level. The inﬂuence of cancer type on response to
Epoetin alfa treatment has been explored in various studies (Abels
et al, 1991; Ludwig et al, 1993; Glaspy et al, 1997; Demetri et al,
1998), and reviewed by Adamson and Ludwig (1999). Some studies
show no effect of cancer type (Abels et al, 1991; Glaspy et al, 1997;
Demetri et al, 1998) and some report a differential effect (Abels,
1993; Ludwig et al, 1993; Adamson and Ludwig, 1999).
The aim of the present study was to investigate further the rela-
tionship between quality-of-life and haemoglobin levels within the
population of anaemic cancer patients diagnosed with one of four
cancers. Other studies have tended to involve patients with a fairly
broad range of tumour sites and as a consequence it is difﬁcult to
be certain of the relevance of the results to individuals of a parti-
cular cancer type. As a measure of HRQoL, two multidimensional
measures, the FACT and the SF-36, were utilised. The SF-36 is a
generic quality of life questionnaire measuring eight multi-item
dimensions (Ware and Sherborne, 1992) which has been widely
validated with varied patient groups (McHorney et al, 1994). While
we expect to ﬁnd similar associations between haemoglobin and
quality-of-life in terms of scores on both the generic SF-36 and
the condition-speciﬁc FACT, we expect the FACT, and in particu-
lar its FACT-An and FACT-F scales, to be more strongly associated
with haemoglobin levels.
PATIENTS AND METHODS
Patients
On the basis of data from previous studies, sample size calculations
suggested that a sample size of 400 patients would be required to
detect clinically signiﬁcant differences in FACT-An score between
haemoglobin groups. It was estimated that this sample size would
be reached by recruiting all cancer patients diagnosed with one of
the four cancers (lung, ovarian, breast or multiple myeloma) who
had appointments in six clinics across the UK between the begin-
ning of May 1999 and the end of October 1999. These patients
were sent an introductory letter that provided details of the study
and informing them that at their next clinic visit they may be asked
to participate in the study. At this visit their haemoglobin levels
were assessed, and if there was adequate clinic time, those patients
with anaemia were asked if they would like to participate in the
study by completing the questionnaires. Anaemia was deﬁned as
haemoglobin 412 g dl
71 in females and haemoglobin 413 g
dl
71 in males (Sweeney et al, 1998). All patients selected were to
have a life expectancy of greater than 3 months. Patients receiving
all active therapies were included (chemotherapy and radiother-
apy). Patients on high dose chemotherapy regimes were excluded.
Study design
This was a cross-sectional, multi-centre study recruiting patients
from six sites across the UK. The study protocol was approved
by the Multi-Centre Research Ethics Committee West Midlands
Region and ratiﬁed by local Ethics Committee. Patients were initi-
ally contacted by post, with a consent form being signed when the
patient arrived at the clinic. A clinical data sheet was completed for
each individual, which included all relevant clinical data (e.g.
haemoglobin level assessed as part of routine assessment, primary
and secondary cancer sites, time elapsed since diagnosis etc.).
The quality-of-life data was collected on the same day by patient
completion of two separate instruments: the FACT and the SF-36.
Data analysis
The FACIT measure includes one General scale (the FACT-G:
Functional Assessment of Cancer Therapy – General) composed
of 27 general questions divided into four primary quality-of-life
domains (physical well-being, social/family well being, emotional
well being and functional well being), plus a 20-item anaemia
speciﬁc scale – ‘Anaemia’. This speciﬁc scale comprises 13 fatigue
related items (‘Fatigue’) and a further seven non-fatigue anaemia
speciﬁc items (‘Non Fatigue’). The resulting FACT-F score is the
sum of the FACT-G and the ‘Fatigue’ items, while the FACT-An
is the sum of all the items – the FACT-G and the ‘Anaemia’ items.
Item scores on the FACT were coded and summed for each dimen-
sion, according to directions in the FACIT Manual (Cella, 1997a).
Each question in the measure is scored, either directly or after
score reversal, from 0 (worst possible QoL) to 4 (best possible
QoL). Resulting scores range from 0 (poor QoL) to the maximum
score (best QoL). The maximum score available differs from scale
to scale, depending on the number of items in the scale (see Table
2). For each SF-36 dimension (Physical Functioning, Role Limita-
tions due to Physical Problems, Role Limitations due to Emotional
Problems, Social Functioning, Mental Health, Energy/Vitality, Pain,
and General Health Perception) item scores were coded, summed
and transformed onto a scale from 0 (worst possible health state)
to 100 (best possible health state). Data are summarised by means
of frequency counts and descriptive statistics. Missing data in the
FACT were treated as the FACIT group recommends, by prorating
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missing (Cella, 1997a). The developers of the SF-36 recommend
the use of an algorithm for substituting missing data, however
Layte and Jenkinson (1997) do not recommend this approach for
the UK SF-36. The SF-36 missing data were not imputed in this
study.
Linear regression analyses (with haemoglobin, which here has a
linear relation with QoL score, used as a continuous variable) were
conducted to investigate the extent to which haemoglobin and
other variables such as age, gender, and time since diagnosis contri-
bute to QoL (SF-36 domains and the FACT subscales). Partial
correlations (correlations with the values of other potentially
confounding variables held constant) were then conducted between
haemoglobin level and the FACT-An and FACT-F scales and the
SF-36 domains to investigate further the relationship between
haemoglobin level and QoL. The partial correlations were
conducted controlling for the confounding variables of age, gender
and time since diagnosis and on the patients with valid data on all
QoL domains. Analyses of covariance (ANCOVA) were used to test
for statistical signiﬁcance in the QoL scores among the four cancer
groups, controlling for the same covariates (age, gender, time since
diagnosis) plus haemoglobin level.
In order to visualise the relationship between haemoglobin level
and QoL, patients were subdivided into four haemoglobin groups
of as equal size as possible at the haemoglobin quartiles: lowest
through 9.8, 9.9 to 10.9, 11.0 to 11.5, and 11.6 through highest.
This maximises the statistical power for comparisons among
groups. Mean quality-of-life scores were compared among the
groups using analysis of variance (ANOVA) and analysis of covar-
iance (ANCOVA), controlling for the same covariates as in the
partial correlation analysis. Post-hoc testing was used to make indi-
vidual comparisons among groups. The signiﬁcance of any linear
trend was assessed within ANOVA by dividing the heterogeneity
among the groups into that due to linear trend and that due to
departures from linear trend. All analyses were carried out using
SPSS version 9.0 for Windows. The signiﬁcance level for all analyse
except the post-hoc tests (for which the P-value was set at P50.01
to control for multiple comparisons) was set at 2-sided P50.05.
However, on account of the large number of analyses performed,
those associations signiﬁcant at the 1% level (P50.01) are consid-
ered most reliable.
RESULTS
Description of sample
On account of low patient recruitment, the recruitment period was
extended for 6 months to the end of May 2000. It was not practic-
able to extend the recruitment period further. One hundred and
seventy-nine anaemic cancer patients completed the study ques-
tionnaires. Across the six study centres, between 90 and 100% of
those approached agreed to participate. Seventy-three per cent
(n=130) were female and 27% (n=47) male. The mean (s.d.) age
of responders was 59 (10) years (min 38, max 84 years). Ninety
per cent of patients (n=159) were currently receiving some form
of treatment, with the majority of them 148 (90%) receiving
chemotherapy compared with seven (4%) receiving radiotherapy
and four (3%) mixed chemotherapy and radiotherapy regimens.
The mean (s.d.) time elapsed since diagnosis was 18 (31) months
(min 1, max 192 months) and the majority of people (89%,
n=137) were outpatients.
In terms of clinical diagnosis, 36% of patients (n=64) had a
diagnosis of breast cancer, 28% (n=51) ovarian cancer, 25%
(n=45) lung cancer and 11% (n=19) multiple myeloma. Thirty-
nine per cent of patients (n=70) had secondary cancer sites. The
mean (s.d.) haemoglobin level within the sample was 10.66
(1.04) g dl
71. The spread and frequency of values is shown in
Figure 1. The haemoglobin distribution was such that, in terms
of the quartiles, 25% of the sample had a level of 9.8 g dl
71 or
lower, 26% a level of between 9.9 and 10.9, 25% between 11.0
and 11.5, and 24% 11.6 or greater. The haemoglobin level did
not differ signiﬁcantly between males and females (mean s.d.)
10.52 (1.08) vs 10.70 (1.03) respectively, t=1.05, df=175, P=0.30).
Table 1 shows the distribution of demographic and clinical data
within primary cancer site groups. The groups differed signiﬁcantly
in terms of a number of factors. As would be expected, the propor-
tion of female patients was highest among those with breast and
ovarian cancer. In terms of the difference in age, there was a signif-
icant linear trend in age from those with breast cancer, who were
the youngest group, through to those with multiple myeloma, who
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Table 1 Demographic and clinical data within primary cancer site groups
Demographic/Clinical factor Breast Ovarian Lung Myeloma ANOVA
mean (SD or n (valid %) n=64 n=51 n=45 n=19 F, P-value w
2, P-value
Mean (s.d.) age, years 53.6 (8.9) 58.7 (10.2) 62.4 (7.5) 68.1 (10.2) 15.1, P50.001
Female, n (%) 61 (97%) 51 (100%) 13 (30%) 5 (26%) 101.2, P50.001
Caucasian, n (%) 59 (94%) 46 (90%) 42 (96%) 19 (100%) 2.50, P=0.46
Married/living as married, n (%) 46 (73%) 36 (71%) 33 (75%) 16 (84%) 1.39, P=0.71
Responsible for children 518 years 18 (29%) 6 (12%) 6 (14%) 0 (0) 11.24, P=0.01
Time since diagnosis, mean (s.d.) months 26.8 (42.5) 19.5 (27.5) 4.4 (4.0) 16.9 (16.7) 4.67, P=0.004 N/A
Currently receiving treatment, n (%) 63 (100%) 49 (96%) 40 (91%) 7 (39%) 63.28, P50.001
Chemotherapy, n (%) 57 (91%) 49 (100%) 37 (93%) 5 (71%)
Radiotherapy, n (%) 4 (6%) 0 (0) 3 (7%) 0 (0)
Mixed chemo and radiotherapy, n (%) 2 (3%) 0 (0) 0 (0) 2 (29%)
Second cancer site, n (%) 37 (58%) 15 (29%) 18 (40%) 0 (0) 23.63, P50.001
Outpatient n (%) 57 (100%) 39 (91%) 22 (63%) 19 (100%) 33.85, P50.001
Haemoglobin level, mean (s.d.) 11.18 (0.72) 10.30 (1.11) 10.48 (1.12) 10.33 (0.91) 9.74, P50.001
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Figure 1 Frequency distribution of haemoglobin levels.
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were also more likely to be currently receiving treatment, to have
been diagnosed for a longer period of time (more than two years
on average), and to have a secondary cancer site. Patients with lung
cancer were more likely to be an inpatient than an outpatient.
Haemoglobin levels also differed among the groups, with post-hoc
tests showing that breast cancer patients had signiﬁcantly higher
haemoglobin levels than all other groups.
Quality of life scores
After prorating the FACT scores, there was missing data for
between one and ﬁve patients, and on the SF-36 domains (which
were not prorated) for between 3 and 16 patients. Table 2 shows
the mean FACT and SF-36 scores for the study patients. Scores
are shown overall and individually by cancer site, adjusted for
the potentially confounding effects of age, gender, haemoglobin
level, and time since diagnosis. While patients with lung cancer
tended to report the worst quality-of-life, on analysis of covariance
(adjusting for age, gender, haemoglobin level, and time since diag-
nosis) most quality-of-life domain scores did not differ signiﬁcantly
among the cancer site groups. There was signiﬁcant heterogeneity
among the groups only in terms of the SF-36 Physical function
domain scores (P=0.007). Post-hoc testing conﬁrmed that indivi-
duals with lung cancer reported signiﬁcantly poorer scores on
these domains than those suffering from breast cancer. Addition-
ally, and although the associations did not reach statistical
signiﬁcance at the 1% level, patients with lung cancer tended to
report poorer SF-36 Physical Functioning than patients with either
ovarian cancer or multiple myeloma (P50.05), poorer SF-36 Role
Physical scores than patients with either breast and ovarian cancer
(P50.05), and poorer FACT non-fatigue scores than patients with
all other cancers (P50.10).
The association between haemoglobin and quality-of-life
Correlations between haemoglobin and quality-of-life Partial
correlations (controlling for age, gender, and time since diagnosis)
between haemoglobin levels and quality-of-life are presented in
Table 3. Signiﬁcant positive correlations were found between
haemoglobin and all the FACT scales (P50.001), indicating that
the higher the haemoglobin level the better the quality-of-life. In
addition, positive correlations were found between haemoglobin
and all of the FACT-G subscales (data not shown). While similar
correlations were found between haemoglobin and the SF-36
domains in that the higher the haemoglobin the better the qual-
ity-of-life, the associations were weaker in some of the domains
(Mental Health and Energy/Vitality) and non-signiﬁcant in two
(Role Mental and Pain).
Positive correlations were observed between haemoglobin and
quality-of-life within all four cancer groups (Table 3). The partial
correlations for subjects with ovarian and breast cancer were of a
smaller magnitude, however, than observed in the overall sample
and did not reach statistical signiﬁcance. Patients with lung cancer
and multiple myeloma showed the strongest associations between
haemoglobin and quality-of-life, with lung cancer patients showing
moderate to strong positive partial correlations between haemoglo-
bin and quality-of-life, with all but one of the FACT scales reaching
statistical signiﬁcance. Sample sizes within the multiple myeloma
group were too small for the estimates of statistical signiﬁcance
to be reliable.
Regression analyses between haemoglobin and quality-of-
life Multiple regression analyses were conducted to examine the
association between haemoglobin and SF-36 and FACT scores
adjusting for the effects of age, gender, and time since diagnosis.
The results of these analyses in terms of the regression coefﬁcients
associated with haemoglobin level are given in Table 3. Haemoglo-
bin level was signiﬁcantly and independently associated with most
FACT and SF-36 QoL domain scores. The regression coefﬁcients
were positive indicating that each unit rise in haemoglobin level
was associated with an increase in QoL.
Table 4 shows the full regression results for the regressions on
the FACT-F and Fact-An domains, and on the SF-36 Physical
Functioning, Physical Role Limitation, Social Functioning, and
Health Perception domains. Age, gender, and time since diagnosis
were entered ﬁrst in to the regression model. In terms of the rela-
tionship with FACT-F and FACT-An, they accounted for 3% of
variability in quality-of-life. Haemoglobin accounted for an addi-
tional 8% of variability. The values of the regression coefﬁcients
indicate that both haemoglobin and age are signiﬁcantly associated
with quality-of-life, with a unit rise in haemoglobin equalling an
average rise of 6.88 units in FACT-F (out of a total score of
160) and an average rise of 8.19 units in FACT-An (out of a total
score of 182). Haemoglobin displays a similar predictive pattern for
the SF-36 Physical Functioning, Role Limitation-Physical and
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Table 2 Adjusted mean (s.e.) QoL scores (FACT and SF-36) for all patients and within primary cancer site groups and results of ANCOVAs (controlling
for age, gender, haemoglobin level, and time since diagnosis; subjects with valid data within each QoL domain)
Breast Ovarian Lung Myeloma All Cancer sites Maximum ANCOVA ANCOVA
n=62
a n=49
a n=44
a n=19
a n=174
a domain score nF , P-value
1) FACT
Fact-G 78.71 (2.20) 79.11 (2.24) 73.45 (2.84) 75.09 (4.01) 77.01 (1.07) 108 163 F=0.69, P=0.56
Fatigue 30.50 (1.98) 30.85 (2.02) 27.90 (2.56) 28.85 (3.63) 29.74 (0.95) 52 167 F=0.23, P=0.88
Non-Fatigue 19.21 (0.66) 19.41 (0.68) 16.95 (0.86) 19.62 (1.22) 18.72 (0.33) 28 167 F=2.36, P=0.073
Anaemia
b 49.71 (2.48) 50.27 (2.53) 44.85 (3.21) 48.47 (4.55) 48.45 (1.20) 80 (52+28) 167 F=0.57, P=0.64
Fact-F
c 108.95 (3.89) 109.68 (3.96) 101.24 (5.03) 104.32 (7.10) 105.58 (1.88) 160 (108+52) 163 F=0.49, P=0.69
Fact-An
d 128.42 (4.39) 129.28 (4.47) 117.91 (5.68) 123.69 (8.01) 125.35 (2.13) 188 (108+80) 163 F=0.74, P=0.53
2) SF-36
Physical function 58.29 (4.02) 49.96 (4.20) 33.66 (5.48) 50.75 (7.32) 49.11 (2.12) 100 155 F=4.14, P=0.007*
Role physical 48.45 (4.29) 49.25 (4.25) 30.11 (5.61) 44.78 (7.90) 43.57 (2.17) 100 164 F=2.59, P=0.055
Role mental 70.41 (4.59) 68.47 (4.73) 62.31 (5.92) 76.17 (8.33) 68.27 (2.23) 100 160 F=1.00, P=0.40
Social functioning 61.58 (4.60) 60.08 (4.73) 52.01 (6.00) 67.77 (8.43) 59.83 (2.27) 100 162 F=1.27, P=0.29
Mental health 74.45 (2.77) 73.09 (2.76) 75.00 (3.50) 69.76 (5.09) 73.66 (1.29) 100 163 F=0.39, P=0.76
Energy/vitality 44.47 (3.75) 45.07 (3.74) 43.45 (4.70) 42.37 (6.68) 43.97 (1.74) 100 164 F=0.04, P=0.99
Pain 79.74 (4.25) 69.32 (4.35) 73.47 (5.44) 67.34 (7.73) 73.80 (2.02) 100 165 F=1.35, P=0.26
Health Perception 57.18 (3.25) 54.04 (3.35) 52.02 (4.49) 54.16 (6.03) 54.75 (1.67) 100 159 F=0.24, P=0.87
aMinimum number of patients;
bAnaemia=fatigue+non-fatigue;
cFACT-F=FACT-G+fatigue;
dFACT-An=FACT-G+anaemia; *lung and breast groups signiﬁcantly different
(P50.01) on post-hoc test.
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accounted for an additional 7% of the variability of these SF-36
scales with a unit rise in haemoglobin equalling an average rise
of 8.00 units (out of a total score of 100). Haemoglobin is slightly
less predictive of Energy/Vitality and Health Perception, providing
only an additional 2–3% variance over the other variables (age,
gender and time since diagnosis).
Difference in quality-of-life among haemoglobin groups In
order to visualise the relationship between haemoglobin level and
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Table 3 Regression and Partial correlation coefﬁcients (controlling for age, gender and time since diagnosis) between the FACT
& SF-36 scales & Hb levels (subjects with valid data on all domains within each scale)
Regression and partial correlation coefﬁcients
over all patients
Partial correlation coefﬁcients (P-value) within each
primary cancer site controlling for age, gender, and
time since diagnosis
Regression Partial
coefﬁcient correlation Breast Ovarian Lung Myeloma
QoL Scales (s.e.) P-value coefﬁcient P-value n=54 n=43 n=35 n=12
(1) FACT n=54 n=43 n=35 n=12
FACT-G 3.41 (1.09) 0.002 0.32 50.001 0.21 (0.12) 0.11 (0.48) 0.30 (0.07) 0.44 (0.11)
Fatigue 3.14 (0.97) 0.001 0.28 0.001 0.23 (0.09) 0.19 (0.21) 0.34 (0.04) 0.20 (0.50)
Non-Fatigue 1.23 (0.33) 50.001 0.30 50.001 0.17 (0.20) 0.21 (0.19) 0.40 (0.01) 0.52 (0.05)
Anaemia 4.37 (1.22) 50.001 0.30 50.001 0.23 (0.09) 0.21 (0.17) 0.37 (0.02) 0.32 (0.27)
FACT-F 6.87 (1.93) 50.001 0.32 50.001 0.24 (0.08) 0.17 (0.27) 0.33 (0.04) 0.35 (0.22)
FACT-An 8.19 (2.18) 50.001 0.33 50.001 0.24 (0.08) 0.18 (0.24) 0.35 (0.03) 0.39 (0.16)
(2) SF-36 n=46 n=37 n=25 n=10
Physical function 6.94 (2.06) 0.001 0.28 0.001 0.19 (0.19) 0.03 (0.83) 0.48 (0.01) 0.57 (0.05)
Role physical 8.60 (2.19) 50.001 0.32 50.001 0.28 (0.06) 0.15 (0.35) 0.45 (0.02) 0.41 (0.19)
Role mental 4.32 (2.31) 0.063 0.15 0.092 0.18 (0.21) 70.04 (0.81) 0.23 (0.25) 0.54 (0.07)
Social functioning 8.59 (2.32) 50.001 0.35 50.001 0.18 (0.23) 0.29 (0.07) 0.36 (0.07) 0.35 (0.27)
Mental health 3.37 (1.33) 0.012 0.25 0.005 0.16 (0.27) 0.19 (0.26) 0.10 (0.61) 0.42 (0.18)
Energy/vitality 4.71 (1.80) 0.010 0.20 0.019 0.17 (0.26) 0.12 (0.45) 0.29 (0.14) 0.25 (0.43)
Pain 1.12 (2.09) 0.59 0.06 0.482 0.24 (0.10) 70.24 (0.15) 0.03 (0.89) 0.51 (0.09)
Health perception 4.44 (1.62) 0.007 0.32 50.001 0.35 (0.02) 0.27 (0.10) 0.01 (0.95) 0.49 (0.11)
Table 4 Results of multiple regression analyses to assess the nature of the independent relationship
between haemoglobin level and QoL (FACT and SF-36 scores)
Outcome variable Predictor variable b Std. Error Sig. R Square
FACT-F
Age 0.51 0.20 0.012 0.03
Gender (female) 3.69 4.63 0.43
Time 70.11 0.06 0.070
Hb 6.88 1.92 50.001 0.11
FACT-An
Age 0.49 0.22 0.032 0.03
Gender (female) 5.03 5.20 0.34
Time 70.13 0.07 0.068
Hb 8.19 2.00 50.001 0.11
SF-36 Physical functioning
Age 0.43 0.22 0.054 0.09
Gender (female) 2.75 4.96 0.58
Time 70.17 0.07 0.015
Hb 6.94 2.06 0.001 0.15
SF-36 Role limitation – Physical
Age 0.08 0.23 0.73 0.02
Gender (female) 8.03 5.30 0.13
Time 70.07 0.07 0.30
Hb 8.60 2.19 50.001 0.11
SF-36 Social functioning
Age 0.39 0.24 0.11 0.02
Gender (female) 7.51 5.61 0.18
Time 70.08 0.07 0.27
Hb 8.59 2.32 50.001 0.10
SF-36 Health Perception
Age 70.17 0.17 0.32 0.12
Gender (female) 10.67 3.95 0.008
Time 70.18 0.05 0.001
Hb 4.44 1.62 0.007 0.16
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haemoglobin groups (divided at the quartiles). There was signiﬁ-
cant overall heterogeneity among the groups in all the FACT
subscales and all of the SF-36 domains with the exception of Pain.
In general, and as also shown by the correlation analyses reported
above, groups with higher haemoglobin levels had better quality-
of-life although the differences were most evident between those
in the highest haemoglobin level group and those in the lowest
group; the subjects in the two intermediate groups reported similar
quality-of-life. This may be a reﬂection of the fact that group 3 has
a fairly narrow range of haemoglobin scores. Indeed, in terms of
the FACT scale, there were signiﬁcant linear trends (with no signif-
icant departures from linear trend) for increasing quality-of-life
with increasing haemoglobin level for each scale. Post-hoc testing
showed speciﬁc differences between the lowest and highest haemo-
globin groupings (groups 1 and 4), between lowest and second
lowest groups (1 and 2), and between the third and highest quar-
tiles (groups 3 and 4). In terms of the SF-36 domains, signiﬁcant
linear trends were found for all domains with the exception of
Pain, with speciﬁc differences being found mainly between the
lowest and highest groups.
DISCUSSION
This study provides further support for the positive relationship
observed in previous studies between haemoglobin level and qual-
ity-of-life in anaemic cancer patients. While the study has a
number of limitations, its strengths include the use of both a
generic and a speciﬁc quality-of-life instrument; the restriction of
study patients to those suffering from one of four cancers; the
inclusion of patients from multiple centres across the UK; and
the ability to control for potential confounding factors to include
age, gender, and time since diagnosis. Weaknesses of the study
include potential selection bias; any effect of missing data; and
the fact that data on various important confounding factors were
not collected, such as information on disease response or progres-
sion, duration and type of chemotherapy, tumour type, nausea and
pain. These factors will clearly inﬂuence both haemoglobin levels
and quality-of-life, and thus the inability to adjust for their effects
is a notable study shortcoming. In addition, the cross-sectional
nature of the study means that the association between changes
in haemoglobin and changes in quality-of-life cannot be assessed.
One hundred and seventy-nine patients completed quality-of-life
assessment forms at the same time as their haemoglobin levels were
assessed. This ﬁgure of 179 is not quite half of the required number
from sample size calculations, a consequence of the low rate of
patient recruitment. However, with the exception of the large
studies reported by Glaspy et al (1997) and Demetri et al (1998)
the study is still relatively large in comparison with similar studies.
Moreover, statistically signiﬁcant associations were observed in this
study between QoL score and haemoglobin level, demonstrating that
the study has sufﬁcient statistical power. Thus, in terms of the speci-
ﬁc quality-of-life instrument, the FACT (Cella, 1997a,b), the higher
the haemoglobin level the fewer the anaemic speciﬁc limitations,
and the less fatigue, reported. Similarly, for the general items, the
higher the haemoglobin level the better the reported quality-of-life.
Higher levels of haemoglobin were thus associated with better physi-
cal, emotional and functional well-being. As was also observed by
Yellen et al (1997), who found that it was the lowest
(511 g dl
71) and highest (413 g dl
71) haemoglobin groups
who differed most, it was the lowest (59.9 g dl
71) and the highest
(411.5 g dl
71) haemoglobin groups that in this study reported the
greatest between-group difference in quality-of-life score; subjects
with intermediate haemoglobin levels generally reported similar
quality-of-life. Statistically signiﬁcant linear trends for increasing
quality-of-life with increasing haemoglobin were, however, found
for all FACT scales (P at least50.01). In terms of the type of patient
group, exploratory analyses found that those with lung or breast
cancer contributed most to the correlations seen between haemoglo-
bin and quality-of-life; when analysed separately these patients
reported much stronger relationships between haemoglobin and
quality-of-life than those with ovarian cancer or myeloma.
In terms of the generic SF-36, similar trends were observed:
higher haemoglobin scores were associated with better Physical
Functioning, Social Functioning, Mental Health, Energy/Vitality
and better Health Perception. All associations but those with Role
Limitation and Pain were statistically signiﬁcant. While there was
a signiﬁcant correlation between the Energy/Vitality domain of
the SF-36 and haemoglobin level, the size of the correlation was
smaller than expected given the higher correlations between the
Fatigue speciﬁc domains on the FACT (FACT-F). This is in line
with our hypothesis that the generic SF-36 will be less sensitive
to anaemia-speciﬁc issues than the condition-speciﬁc FACT-An
and FACT-F. The SF-36 Energy/Vitality domain comprises just four
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Table 5 Adjusted mean (s.e.) QoL scores (FACT and SF-36) in the Hb groups and the results of ANCOVAs (controlling for age, gender, and time since
diagnosis; subjects with valid data within each QoL domain)
Haemoglobin groups Results of ANCOVAs ANOVA
(1) (2) (3) (4) Groups sig diff (50.01) Linear trend
4=9.8 9.9–10.9 11.0–11.5 11.6+ nF , P-value on post-hoc test F, P-value
(1) FACT n=38
a n=44
a n=41
a n=41
a n=163
a
Fact-G 72.15 (2.23) 76.76 (2.04) 75.72 (2.14) 83.82 (2.14) 163 F=5.06, P=0.002 1v4 3v4 F=7.01, P=0.009
Fatigue 23.71 (1.98) 31.21 (1.83) 28.52 (1.95) 35.46 (1.92) 167 F=6.41, P50.001 1v2 1v4 F=10.65, P=0.001
Non-Fatigue 16.49 (0.68) 19.42 (0.63) 18.55 (0.67) 20.45 (0.66) 167 F=6.20, P=0.001 1v2 1v4 F=14.39, P50.001
Anaemia 40.20 (2.49) 50.62 (2.30) 47.06 (2.45) 55.91 (2.41) 167 F=7.24, P50.001 1v2 1v4 F=13.25, P50.001
Fact-F 95.36 (3.91) 107.72 (3.57) 104.15 (3.76) 119.31 (3.75) 163 F=6.71, P50.001 1v4 3v4 F=10.68, P=0.001
Fact-An 111.82 (4.42) 127.13 (4.04) 122.71 (4.26) 139.94 (4.25) 163 F=7.20, P50.001 1v4 3v4 F=12.33, P=0.001
(2) SF-36 n=36
a n=41
a n=38
a n=37
a n=155
a
Physical functioning 36.08 (4.15) 52.04 (3.94) 49.20 (4.17) 59.93 (4.18) 155 F=5.59, P=0.001 1v2 1v4 F=17.79, P50.001
Role physical 29.79 (4.52) 43.75 (4.18) 44.58 (4.40) 56.82 (4.39) 164 F=6.01, P=0.001 1v4 F=17.54, P50.001
Role mental 59.23 (4.74) 72.21 (4.31) 66.13 (4.60) 75.92 (4.65) 160 F=2.47, P=0.064 F=4.51, P=0.035
Social functioning 44.59 (4.83) 60.28 (4.41) 62.00 (4.64) 70.48 (4.70) 162 F=4.94, P=0.003 1v4 F=12.81, P50.001
Mental health 67.90 (2.76) 72.80 (2.56) 73.99 (2.77) 79.98 (2.66) 163 F=3.30, P=0.022 1v4 F=9.35, P=0.003
Energy/vitality 35.84 (3.61) 43.55 (3.38) 40.90 (3.61) 56.49 (3.54) 164 F=6.08, P=0.001 1v4 2v4 3v4 F=12.38, P=0.001
Pain 70.27 (4.30) 74.43 (4.02) 69.20 (4.29) 81.34 (4.17) 165 F=1.73, P=0.163 F=2.82, P=0.095
Health perception 48.43 (3.43) 52.63 (3.09) 55.55 (3.21) 63.31 (3.25) 159 F=3.52, P=0.017 1v4 F=16.18, P50.001
an=Minimum number of patients in each group
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you feel worn out’, ‘ Did you feel tired’), compared with the FACT-
F scale comprising 13 items relating to fatigue related aspects of
anaemia. Again, exploratory analyses found that those with lung
or breast cancer contributed most to the correlations seen.
In conclusion, this study has utilised a well-validated quality-of-
life measure, developed speciﬁcally for use with anaemic cancer
patients, and concentrated on four types of primary cancer to
provide reliable information on the nature of the association
between haemoglobin level and quality-of-life in anaemic cancer
patients. The nature of the observed associations may be of use
in the evaluation of the effectiveness of speciﬁc treatments to
improve the quality-of-life of anaemic cancer patients. In particu-
lar, while no information on haemoglobin and quality-of-life
change has been collected in this study, the data are consistent with
such observations and suggest that the raising of haemoglobin in
anaemic cancer patients would improve their quality-of-life. In
terms of the psychometric properties of the condition-speciﬁc
FACT, the instrument has been shown to provide a more sensitive
measure than the generic SF-36 to quality-of-life issues in these
anaemic cancer patients and may thus be used alone to assess qual-
ity-of-life in this patient group.
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